Lake Street analyst Ben Klieve maintained a Buy rating on Arcadia Biosciences (RKDA – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $2.04.
Klieve covers the Consumer Defensive sector, focusing on stocks such as Vital Farms, MGP Ingredients, and Calavo Growers. According to TipRanks, Klieve has an average return of 7.7% and a 46.33% success rate on recommended stocks.
Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $11.00.
RKDA market cap is currently $2.78M and has a P/E ratio of -0.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcadia Biosciences (RKDA) Company Description:
Arcadia Biosciences, Inc. is an agricultural biotechnology company which engages in the development of agricultural products for the improvement of the environment and human health. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. The company’s portfolio of agricultural productivity traits includes Nitrogen Use Efficiency, Water Use Efficiency, Drought Tolerance, Salinity Tolerance and Herbicide Tolerance. It has presence in the United States, Africa, India, the United Arab Emirates, Belgium, France and Canada. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.
Read More on RKDA:
